After-Hours Movers 6/10: MBRX, PALM, PLXS Higher; ATPG, ATU, VMC...

Courtesy StreetInsider.com News Articles  Wed, 06/10/2009 - 15:29

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) 26.4% HIGHER; announced that its four year research collaboration with Merck & Co., Inc.

(NYSE: MRK), focused on the discovery and development of AMP protein kinase activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.

In addition, under an amended agreement, Merck has agreed to pay Metabasis a one-time fee of $6 million that satisfies all future obligations for milestones and royalty payments.

Metabasis warned that even with...

Tags:

 

Related items

Merck board approves $5 billion in stock buybacks
Merck & Co. Inc. said Wednesday its board of directors approved the buyback of up to $5 billion in common stock for the drug developer's treasury.

Merck loses $473M tax appeal in Schering case
A three-judge federal appeals court panel on Monday rejected an attempt by drugmaker Merck & Co. to win a refund of nearly $500 million in taxes assessed two decades ago.

Selected first-quarter drug sales for Merck & Co.
Here are sales figures for the first quarter for Merck & Co.'s 10 top-selling drugs:

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...

Uniden TRU9496 2-Line Corded/Cordless Digital...
With the Uniden TRU9496 5.8 GHz Digital 2-Line Expandable Phone System is the next generation of 5.8 GHz cordless phones. It's a full-featured digital answerer, with a Dialing keypad and a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com